FDA 483 - BioLife Plasma Services LP - December 16, 2021

An FDA inspection of BioLife Plasma Services LP in Jacksonville, FL, revealed two significant observations. The facility failed to ensure donor privacy during health history screenings and did not maintain sterile conditions during phlebotomy site preparation. These issues indicate potential risks to donor confidentiality and product sterility.